Skip to content

Human Epstein–Barr virus IgM Lateral flow dipstick kit 4573

$487.00

Summary

  • Mikrogen diagnostik lateral flow device (dipstick) for research use (RUO)
  • Human Epstein–Barr virus IgM Lateral flow dipstick kit 4573
  • Suitable for IgM detection
  • Ready-to-use
  • 20 tests
SKU: 4573 Category: Tags: , ,
Weight1 lbs
Dimensions9 × 5 × 2 in
target

Human Epstein–Barr virus IgM

species reactivity

Human Epstein–Barr virus

applications

Lateral flow (dipstick)

assay type

Indirect & qualitative

available sizes

20 test kits

Human Epstein–Barr virus IgM Lateral flow dipstick kit 4573

kit
Assay type
Sandwich assay, lateral flow (dipstick)
Research area
Infectious Disease
Sample type
Serum, plasma, whole blood
Components
10X Wash Buffer100 mL
TMB Substrate40 mL
Milk Powder5 g
Instructions for Use1 Each
Evaluation Form1 Each
Test Strips2 kits of [2 Vials x 10 Each]
Anti-Human IgGM Conjugate500 μL
Positive Control140 μL
Negative Control140 μL
Storage
Store at 2-8°C.
Additional information
Mikrogen recomLine Borrelia Tests

Mikrogen recomLine Borrelia Tests are serological, qualitative in vitro tests with recombinantly produced, highly specific and immunodominant Borrelia antigens. All specific antibodies against all known Lyme disease-causing Borrelia species (B. burgdorferi sensu stricto, B. garinii, B. afzelii, B. spielmanii, and B. bavariensis) can be detected on one test strip.

The recomLine Borrelia tests are used to confirm the results of screening enzyme immunoassays.

Advantages
  • Optimal imaging without cross-reacting Borrelia proteins.
  • Identification of early and late infection status through different, typical antigen band patterns.
  • Standardized serum CSF analysis possible, for detection of antibody index in suspected cases of Lyme neuroborreliosis.
  • Separate detection of IgG and IgM antibodies.
  • Simple and clear interpretation due to easy-to-read banding.
  • Compliant with MiQ Lyme Borreliosis1 and DIN 58969-442.
  • Partial and full automation, software-based evaluation (recomScan), and integration with laboratory information system possible.
  • Highest sensitivity and specificity by using recombinant, immunodominant antigens.
Bands
AntigenTribe
p100B. afzelii
VIsEDifferent Borrelia genospecies
p58B. garinii
p41B. burgdorferi sensu stricto
p39B. afzelii
OspAB. afzelii
OspCB. burgdorferi sensu stricto, B. afzelii, B. garinii, B. spielmanii
p18B. burgdorferi sensu stricto, B. afzelii, B. garinii, B. spielmanii, B. bavariensis
target relevance
Organism
Borrelia burgdorferi
Structure and strains
Borrelia burgdorferi is a bacterial species of the spirochete class in the genus Borrelia, and is one of the causative agents of Lyme disease in humans. Along with a few similar genospecies, some of which also cause Lyme disease, it makes up the species complex of Borrelia burgdorferi sensu lato. The complex currently comprises 20 accepted and 3 proposed genospecies.B. burgdorferi sensu stricto exists in North America and Eurasia and until 2016 was the only known cause of Lyme disease in North America. Borrelia species are Gram-negative.
Disease
Pathogens Borrelia burgdorferi is the infectious agent of Lyme-Borreliosis. B. burgdorferi sensu stricto, B. garinii, B. afzelii and B. spielmanii are the most important human pathogens of the genospecies Borrelia burgdorferi sensu lato. All four species are distributed throughout Europe in temperate climate zones. Reservoirs for the bacteria include a variety of mammals, particularly mice. The bacteria are transmitted to human hosts by infected ticks.

Lyme-Borreliosis is a multisystemic disease. Dermal manifestations with Erythema migrans (EM) as a characteristic symptom of early disease are displayed by 70 to 90 % of infected persons. In addition to non-specific symptoms, in particular neurological disorders, e. g. Morbus Bannwarth, may be observed between a few weeks and several months post infection as signs of a systemic disease with single or multiple organ involvement. Development of late-stage symptoms may occur up to several years after the tick bite and are characterized by dermatological diseases (Acrodermatitis chronica athrophicans), diseases of the joints (Lyme-Arthritis), and neurological diseases (chronical encephalomyelitis).
Detection and diagnosis
Due to the complexity of the clinical picture and the generally unspecific symptoms, serology is the appropriate method to ensure an optimal diagnosis. It is recommended to adopt a logical step-wise approach for serological diagnosis, initially using a sensitive screening assay with subsequent confirmation by another specific test.

Publications

pmidtitleauthorscitation
We haven't added any publications to our database yet.
Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.

relevant to this product
4573 protocol
#
Please enter your product and batch number here to retrieve product datasheet, SDS, and QC information.

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.